Alopecia areata

International Journal of Dermatology

Volumn 46, Issue 2, 2007, Pages 121-131

  Wasserman, Dan ^a   Guzman Sanchez, Daniela Araucaria ^a   Scott, Kimberly ^b   Mcmichael, Amy ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN A; DERMATOLOGICAL AGENT; DESOXIMETASONE; DEXAMETHASONE; DIPHENCYPRONE; DITHRANOL; ETANERCEPT; FLUOCINOLONE; GAMMA INTERFERON; HALCINONIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 5; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; METHOXSALEN; METHYLPREDNISOLONE; MINOXIDIL; PREDNISONE; SQUARIC ACID DIBUTYL ESTER; TACROLIMUS; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE;

ADRENAL DISEASE; ALOPECIA AREATA; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; AUTOIMMUNE DISEASE; BEHAVIOR DISORDER; BONE DISEASE; BURNING SENSATION; CATARACT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COLOR VISION DEFECT; CONTACT URTICARIA; CUSHING SYNDROME; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EMOTIONAL DISORDER; ERYTHEMA; ERYTHEMA MULTIFORME; EYELID EDEMA; FACE EDEMA; FAMILY HISTORY; FLU LIKE SYNDROME; FOLLICULITIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; GINGIVA HYPERPLASIA; HAIR LOSS; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; HYPOPIGMENTATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION SENSITIVITY; LIVER TOXICITY; LOW DRUG DOSE; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; MELANOMA; MOOD DISORDER; MYALGIA; NEPHROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOPOROSIS; PATHOGENESIS; PHYSICAL STRESS; PLASTIC SURGERY; PRURITUS; PUVA; REVIEW; SIDE EFFECT; SKIN IRRITATION; TATTOO; TREMOR; VITILIGO; XERODERMA;

ADULT; ALOPECIA AREATA; ANTHRALIN; CHILD; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOTHERAPY; MINOXIDIL; PUVA THERAPY; VASODILATOR AGENTS;

EID: 34247594405     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03193.x     Document Type: Review

References (153)

1. Olsen EA. Hair, in Fitzpatrick's Dermatology in General Medicine. In: Freedberg IM. New York: McGraw-Hill, 2003: 641-643.
2. Sehgal VN, Jain S. Alopecia areata: Clinical perspective and an insight into pathogenesis. J Dermatol 2003; 30: 271-289.
3. Olsen EA, Hordinsky MK. Price VH, et al. Alopecia Areata Investigational Assessment Guidelines - Part II. J Am Acad Dermatol 2004; 51: 440-447.
4. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70: 628-633.
5. Dawber RP, de Berker DA. Disorders of Hair. Boston: Blackwell Science, 1998.
6. Tan E, Tay Y-K, Goh Ch-L, et al. The pattern of alopecia areata in Singapore - a study of 219 Asians. Int J Dermatol 2002; 41: 748-753.
7. Tan E, Tay YK, Giam YCh. A clinical study of childhood alopecia areata in Singapore. Pediatric Dermatol 2002; 19: 298-301.
8. Camacho F. Alopecia areata. Clinical characteristics and dermatopathology, in Trichology: Diseases of the pilosebaceous follicle 1997, Madrid, Aula Medical Group, S. A. 471-440.
9. Berker D, Baran D. RPR Handbook of Diseases of the Nails and Their Management. Oxford: Blackwell Science Ltd, 2004.
10. Cline DJ. Changes in hair color. Dermatol Clin 1988; 6: 295-303.
11. Giovanni S. Recherches sur l'histologie pathologique de la pelade. Ann Dermatol Syphiligr 1991; 3: 923-957.
12. Restrepo R, Mckee Ph, Calonje E. Diseases of the hair. In: Mckee Ph, Calonje E, Granter SR, eds. Pathology of the Skin with Clinical Correlations. 3th edn. Philadelphia: Elsevier Mosby, 2005: 1073-1079.
13. Loffreda M. Inflammatory diseases of hair follicles, sweat glands and cartilage. In: Elden D, Elantsas R, Bernett J, et al. eds. Lever's Histopathology of the Skin, 9th edn. Philadelphia: Lippincott Williams & Wilkins, 2005: 483-485.
14. Ghersetich I, Campanile G, Loti T. Alopecia areata: Immunohistochemistry and ultrastructure of infiltrate and identification of adhesion molecule receptors. Int J Dermatol 1996; 35: 28-33.
15. Todes-Taylor N, Turner R, Wood S, et al. T cell subpopulations in alopecia areata. J Am Acad Dermatol 1984; 11: 216-223.
16. Hull SM, Nutbrown M, Pepall L, et al. Immunohistologic and ultrastructural comparison of the dermal papilla and hair follicle bulb from "active"and "normal"areas of alopecia areata. J Invest Dermatol 1991; 96: 673-681.
17. Igarashi R, Moroashi M, Takeuchi S. Immunofluorescence studies on complement components in the hair follicles of normal scalp and of scalp affected by alopecia areata. Acta Derm Venreol 1981; 61: 131-135.
18. Headington JT. Abstract: The histopathology of alopecia areata. J Invest Dermatol 1991; 96: 69S.
19. Whiting DA. Histopathology of alopecia areata in horizontal sections of scalp biopsies. J Invest Dermatol 1995; 104: 26S-27S.
20. Messenger AG, Bleehen SS, Alopecia areata. Light and electron microscopic pathology of the regrowing white hair. Br J Dermatol 1984; 110: 155-162.
21. Messenger AG, Slater DN, Bleehen SS. Alopecia areata: Alterations in the hair growth cycle and correlation with the follicular pathology. Br J Dermatol 1986; 114: 337-347.
22. Bowen J. Two epidemics of alopecia areata in an asylum for girls. J Cutan General-Uri Dis 1899; 17: 399-404.
23. Davis H. Epidemic alopecia areata. Br J Dermatol 1914; 26: 204-210.
24. Stankler L. Synchronous alopecia in 2 siblings: A possible viral aetiology. Lancet 1979; 1: 1303-1304.
25. Tosti A, La Placa M, Placucci F, et al. No correlation between CMV and alopecia areata. J Invest Dermatol 1996; 107: 443.
26. Plumbe S. A Practical Treatise on the Diseases of the Skin, 4th edn. London: Printed for Sherwood, Gilber and Piper, 1837.
27. Ruiz-Doblado S, Carrizosa A, Garcia-Hernandez MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol 2003; 42: 434-437.
28. Yang S, Yang J, Liu JB, et al. The genetic epidemiology of alopecia areata in China. Br J Dermatol 2004; 151: 16-23.
29. Lenane P, Pope E, Krafchik B. Congenital alopecia areata. J Am Acad Dermatol 2005; 52: S8-S11.
30. McMichael AJ. The genetic epidemiol autoimmune pathogenesis alopecia areata. J Eur Acad Dermatol Venereol 1997; 9: 36-43.
31. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002; 27: 405-409.
32. 3H/HeJ mice. J Invest Dermatol 2003; 120: 771-775.
33. 3H/HeJ mouse model. J Invest Dermatol 2004; 123: 294-297.
34. Kavak A, Baykal C, Ozarmagan G, et al. HLA in alopecia areata. Int J Dermatol 2000; 39: 589-592.
35. 03 alleles are associated with alopecia areata. J Invest Dermatol 1994; 103: 758-763.
36. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16: 1215.
37. 1 alleles with alolpecia areata in Chinese Hans. Arch Dermatol Res 2005; 297: 201-209.
38. Barahmani N, de Andrade M, Slusser JP, et al. Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata. J Invest Dermatol 2006; 126: 74-78.
39. Perret C, Brocker EB, Wiesner-Menzel L, et al. In situ demonstration of T cells in alopecia areata. Arch Dermatol Res 1982; 27: 155-158.
40. McElwee KJ, Hoffmann R. Alopecia areata - animal models. Clin Exp Dermatol 2002; 27: 410-417.
41. 4+ and CD8+ T lymphocytes: Transfer to human scalp explants on Prkdc (SCID) mice. Arch Dermatol 2002; 138: 916-922.
42. Friedmann PS. Alopecia areata auto-immunity. Br J Dermatol 1981; 105: 153-157.
43. Gilhar A, Kalish R. Alopecia areata: A tissue-specific autoimmune disease of the hair follicle. Autoimmunity Rev 2006; 5: 64-69.
44. 3H/HeJ mice with alopecia areata-like hair loss. J Invest Dermatol 1997; 109: 329-333.
45. McElwee KJ, Pickett P, Oliver RF. The DEBR rat, alopecia areata and autoantibodies to the hair follicle. Br J Dermatol 1996; 134: 55-63.
46. Muller HK, Rook AJ, Kubba R. Immunohistology and autoantibody studies in alopecia areata. Br J Dermatol 1980; 102: 609-610.
47. Yano S, Ihn H, Nakamura K, et al. Antinuclear and antithyroid antibodies in 68 Japanese patients with alopecia areata. Dermatology 1999; 199: 191.
48. Tobin DJ, Orentreich N, Fenton DA. Anitbodies to hair follicles in alopecia areata. J Invest Dermatol 1994; 102: 721-724.
49. Tobin DJ, Hann SK, Song MS, et al. Hair follicle structures targeted by antibodies in patients with alopecia areata. Arch Dermatol 1997; 133: 57-61.
50. Cunliffe WJ, Hall R, Newell DJ, et al. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968; 80: 135-139.
51. Wang SJ, Shohat T, Vadheim C, et al. Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata. Am J Med Genet 1994; 51: 234-239.
52. Werth VP, White WL, Sanchez MR, et al. Incidence of alopecia areata in lupus erythematosus. Arch Dermatol 1992; 128: 368-371.
53. Suzuki S, Shimoda M, Kawamura M, et al. Myasthenia gravis accompanied by alopecia areata: Clinical and immunogenetic aspects. Eur J Neurol 2005; 12: 566-570.
54. Hedstrand H, Perheentupa J, Ekwall O, et al. Antibodies against hair follicles are associated with alopecia totalis in autoimmune polyendocrine syndrome type I. J Invest Dermatol 1999; 113: 1054-1058.
55. Corazza GR, Andreani ML, Venturo N, et al. Report of a new association. Gastroenterology 1995; 109: 1333-1337.
56. Muller SA, Winkelmann RK. Alopecia areata. An evaluation of 736 patients. Arch Dermatol 1963; 88: 290-297.
57. Silverstein AM, Rose NR. There is only one immune system! The view from immunopathology. Semin Immunol 2000; 12: 173-178.
58. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 340-350.
59. Pakala SV, Chivetta M, Kelly CB, et al. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 1999; 189: 1053-1062.
60. Barfield RC, Otto M, Houston J, et al. One-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004; 6: 1-6.
61. Hoffmann R, Eicheler W, Huth A, et al. Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. Arch Dermatol Res 1996; 288: 153-156.
62. Hoffmann R, Eicheler W, Wenzel E, et al. IL-1β-induced inhibition of hair growth in vitro is mediated by CAMP. J Invest Dermatol 1997; 108: 40-42.
63. 3H/HeJ mice. J Invest Dermatol 2005; 125: 945-951.
64. Shohat M, Mimouni D, Ben-Amital D, et al. In vitro cytokine profile in childhood alopecia areata and the inmunomodulatory effects of AS-101. Clin Exp Dermatol 2005; 30: 432-434.
65. Lortkipandize NT, Tevzadze MSh, Kamkamidze GK. Interferon gamma and neopterin in alopecia areata. Georgian Med News 2005; 123: 53-57.
66. Tanyasiri K, Hira K, Mitsuishi K, et al. Interleukin-16 in patients with alopecia areata. J Dermatol Sci 2005; 37: 55-57.
67. Ross EK, Shapiro J. Management of hair loss. Dermatol Clin 2005; 23: 227-243.
68. Shimmer BP, Parker KL. Goodman's and Gillman's: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001:1661-1663.
69. Kalkoff KW, Macher E. [Growing of hair in alopecia areata and maligna after intracutaneous hydrocortisone injection.] Hautarzt 1958; 9: 441-451.
70. Porter D, Burton JL. A Comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971; 85: 272-273.
71. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42: 549-566.
72. Whiting DA. The Treatment Alopecia Areata Cutis 1987; 40: 247-250.
73. Bowen J. Two epidemics of alopecia areata in an asylum for girls. J Cutan General-Uri Dis 1999; 17: 399-404.
74. Price VH. Treatment of hair loss. New Engl J Med 1999; 341: 964-973.
75. Sawaya ME, Hordinsky MK. Glucocorticoid regulation of hair growth in alopecia areata. J Invest Dermatol 1995; 104: 30S.
76. Fiedler VC, Alaiti S. Treatment of alopecia areata. Dermatol Clin 1996; 14: 733-737.
77. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. efficacy side effects including histologic study ensuing localized acneiform response. Dermatologica 1970; 141: 193-202.
78. Leyden JL, Kligman AM. Treatment of alopecia areata with steroid solution. Arch Dermatol 1972; 106: 924.
79. Cerottini JP, Panizzon RG, de Viragh PA. Multifocal alopecia areata during systemic cyclosporine A therapy. Dermatology 1999; 198: 415-417.
80. Montes LF. Topical halcinonide in alopecia areata and in alopecia totalis. J Cutan Pathol 1977; 4: 47-50.
81. Tosti A, Piraccini BM, Pazzaglia M, et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003; 49: 96-98.
82. Dillaha CJ, Rothman S. Therapeutic experiments in alopecia areata with orally administered cortisone. J Am Med Assoc 1952; 150: 546-550.
83. Burton JL, Shuster S. Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol 1975; 55: 493-496.
84. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128: 1467-1473.
85. Friedli A, Labarthe MP, Engelhardt E, et al. Pulse methylprednisolone therapy for severe alopecia areata: An open prospective study of 45 patients. J Am Acad Dermatol 1998; 39: 597-602.
86. Assouly P, Reygagne P, Jouanique C, et al. Intravenous pulse methylprednisolone therapy for severe alopecia areata. An open study of 66 patients. Ann Dermatol Venereol 2003; 130: 326-330.
87. Thappa DM, Vijaikumar S. Intravenous dexamethasone pulse therapy for extensive alopecia areata. Indian J Dermatol 1999; 44: 187-190.
88. Buhl AE. Minoxidil's action in hair follicles. J Invest Dermatol 1991; 96: 73S-74S.
89. Vanderveen EE, Ellis CN, Kang S, et al. Topical minoxidil for hair regrowth. J Am Acad Dermatol 1984; 11: 416-421.
90. Fiedler-Weiss VC, Buys CM. Response to minoxidil in severe alopecia areata correlates with T lymphocyte stimulation. Br J Dermatol 1987; 117: 759-763.
91. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987; 16: 730-736.
92. Ranchoff RE, Bergfeld WF, Steck WD, et al. Extensive alopecia areata. Results of treatment with 3% top minoxidil cleve. Clin J Med 1989; 56: 149-154.
93. Fiedler VC, Wendrow A, Szpunar GJ, et al. Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990; 126: 756-759.
94. Fiedler VC. Alopecia areata: Current therapy. J Invest Dermatol 1991; 96: 69S.
95. Fransway AF, Muller SA. 3 Percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. Cutis 1988; 41: 431-435.
96. Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987; 123: 1491-1493.
97. Schmoeckel C, Weissmann I, Plewig G, et al. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979; 115: 1254-1255.
98. Nelson DA, Spielvogel RL. Anthralin therapy for alopecia areata. Int J Dermatol 1985; 24: 606-607.
99. Thappa DM, Vijayikumar M. Alopecia areata. Indian J Dermatol Venereol Leprol 2001; 67: 188-188.
100. McMichael AJ. Topical sensitizers in alopecia areata. Dermatol Nurs 2004; 16: 333-336.
101. Happle R. Topical immunotherapy in alopecia areata. J Invest Dermatol 1991; 96: 71S-72S.
102. Brocker EB, Echternacht-Happle K, Hamm H, et al. Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: Modulation by topical immunotherapy. J Invest Dermatol 1987; 88: 564-568.
103. Rosenberg EW, Drake L. In: Discussion of Dunaway DA. Alopecia areata. Arch Dermatol 1976; 112: 256.
104. Kratka J, Goerz G, Vizethum W, et al. Dinitrochlorobenzene: Influence on the cytochrome P-450 system and mutagenic effects. Arch Dermatol Res 1979; 266: 315-318.
105. Strobel R, Rohrborn G. Mutagenic cell transforming activities 1-chlor-2,4-dinitrobenzene (DNCB) squaric- acid-dibutylester (SADBE) Arch Toxicol 1980; 45: 307-314.
106. Happle R, Bucher U, Kalveram KJ, et al. Contact allergy as a therapeutic tool for alopecia areata: Comparison between dinitrochlorobenzene and squaric acid dibutyl ester. Arch Dermatol Res 1979; 264: 101-102.
107. Tosti A, De Padova MP, Minghetti G, et al. Therapies versus placebo in the treatment of patchy alopecia areata. J Am Acad Dermatol 1986; 15: 209-210.
108. Shapiro J, Tan J, Ho V, et al. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: A clinical and immunopathologic evaluation. J Am Acad Dermatol 1993; 29: 729-735.
109. Pardasani AG, Turner E, McMichael AJ. Squaric acid dibutylester: indications for use and efficacy in alopecia areata. Arch Dermatol 2001; 137: 970-972.
110. Wilkerson MG, Henkin J, Wilkin JK, et al. Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol 1985; 13: 229-234.
111. Breslow BM, Haynie R, Mirra J. Synthesis of diphencyclopropenone. J Am Chem Soc 1959; 81: 247-248.
112. Van der Steen PH, Happle R. Top immunotherapy alopecia areata. Dermatol Clin 1993; 11: 619-622.
113. Hull SM, Pepall L, Cunliffe WJ. Alopecia areata in children: Response to treatment with diphencyprone. Br J Dermatol 1991; 125: 164-168.
114. Van der Steen PH, Boezeman JB, Happle R. Topical immunotherapy for alopecia areata: Re-evaluation of 139 cases after an additional follow-up period of 19 months. Dermatology 1992; 184: 198-201.
115. Hull SM, Cunliffe WJ. Successful treatment of alopecia areata using the contact allergen diphencyprone. Br J Dermatol 1991; 124: 212-213.
116. Hoting E, Boehm A. Therapy of alopecia areata with diphencyprone. Br J Dermatol 1992; 127: 625-629.
117. Schuttelaar ML, Hamstra JJ, Plinck EP, et al. Alopecia areata in children: Treatment with diphencyprone. Br J Dermatol 1996; 135: 581-585.
118. Cotellessa C, Peris K, Caracciolo E, et al. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 2001; 44: 73-76.
119. Ross E, Shapiro J. Management of hair loss. Dermatol Clin 2005; 23: 227-243.
120. McMichael AJ, Henderson RL Jr. Topical sensitizers in alopecia areata. Dermatol Nurs 2004; 16: 333-336.
121. Perret CM, Steijlen PM, Zaun H, et al. Erythema multiforme-like eruptions a rare side effect top immunotherapy with diphenylcyclopropenone. Dermatologica 1990; 180: 5-7.
122. Higgins E, du Vivier A. Topical immunotherapy: Unapproved uses, dosages or indications. Clin Dermatol 2002, 515-521.
123. Duhra P, Foulds IS. Persistent vitiligo induced by diphencyprone. Br J Dermatol 1990, 123: 4no 15-416.
124. Ree K. Reduction of Langerhans cells in human epidermis during PUVA therapy: A morphometric study. J Invest Dermatol 1982; 78: 488-492.
125. Weissmann I, Hofmann C, Wagner G, et al. PUVA-therapy for alopecia areata. An invest study arch. Dermatol Res 1978; 262: 333-336.
126. Lassus A, Kianto U, Johansson E, et al. PUVA treatment for alopecia areata. Dermatologica 1980; 161: 298-304.
127. Claudy AL, Gagnaire D. PUVA treatment alopecia areata. Arch Dermatol 1983; 119: 975-978.
128. Healy E, Rogers S. PUVA treatment for alopecia areata - does it work? A retrospective review of 102 cases. Br J Dermatol 1993; 129: 42-44.
129. Behrens-Williams SC, Leiter U, Schiener R, et al. The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. J Am Acad Dermatol 2001; 44: 248-252.
130. Whitmont K, Cooper A. PUVA treatment of alopecia areata totalis and universalis: A retrospective study. Australas J Dermatol 2003; 44: 106-109.
131. Van der Schaar WW, Sillevis Smith JH. An evaluation of PUVA-therapy for alopecia areata. Dermatologica 1984; 168: 250-252.
132. Taylor CR, Hawk JL. PUVA treatment of alopecia areata partialis, totalis and universalis: Audit of 10 years' experience at St John's Institute of Dermatology. Br J Dermatol 1995; 133: 914-918.
133. Mohamed Z, Bhouri A, Jallouli A, et al. Alopecia areata treatment with a phototoxic dose of UVA and topical 8-methoxypsoralen. J Eur Acad Dermatol Venereol 2005; 19: 552-555.
134. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336: 1041-1045.
135. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
136. Taylor M, Ashcroft AT, Messenger AG. Cyclosporin A prolongs human hair growth in vitro. J Invest Dermatol 1993; 100: 237-239.
137. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126: 339-350.
138. Ferrando J, Grimalt R. Partial response of severe alopecia areata to cyclosporine A. Dermatology 1999; 199: 67-69.
139. Paquet P, Arrese EJ, Pierard GE. Oral cyclosporin alopecia areata. Dermatology 1992; 185: 314-315.
140. Shapiro J, Lui H, Tron V, et al. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: A clinical and immunopathologic evaluation. J Am Acad Dermatol 1997; 36: 114-117.
141. Lawrence ID. Tacrolimus (FK506): Experience in dermatology. Dermatol Ther 1998; 5: 74-84.
142. Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol 1994; 102: 160-164.
143. Jiang H, Yamamoto S, Kato R. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. J Invest Dermatol 1995; 104: 523-525.
144. McElwee KJ, Rushton DH, Trachy R, et al. Topical FK506: A potent immunotherapy for alopecia areata? Studies using Dundee exp bald rat model. Br J Dermatol 1997; 137: 491-497.
145. Thiers BH. Topical tacrolimus: Treatment failure a patient with alopecia areata. Arch Dermatol 2000; 136: 124.
146. Feldman KA, Kunte C, Wollenberg A, et al. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 2002; 147: 1031-1032.
147. Price V, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005; 52: 138-139.
148. McMichael AJ. The new biologics in psoriasis: Possible treatments for alopecia areata. J Invest Dermatol Symp Proc 2003; 8: 217-218.
149. Strober B, Siu K, Alexis A, et al. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. J Am Acad Dermatol 2005; 52: 1082-1084.
150. Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 2005; 141: 759-760.
151. Ettefagh L, Neodorost S, Mirmirani P. Alopecia areta in a patient using infliximab: New insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2004; 140: 1012.
152. Barankin B, Taher M, Wasel N. Successful hair transplant of eyebrow alopecia areata. J Cutan Medical Surg 2006; 2: [Epub ahead of print].
153. Garg G, Thami GP. Micropigmentation: Tattooing for medical purposes. Dermatol Surg 2005; 31: 928-931.